Gilead Sciences, Inc.

Gilead Calistoga LLC

Stephane Perreault

Jennifer Anne Treiberg

Leena Patel

Gary Bruce Phillips

Jayaraman Chandrasekhar

Suet Chung Yeung

Jerry B Evarts

Musong Kim

Julian Andrew Codelli

Kirk L Stevens

Kassandra F Sedillo

Kevin S Currie

Joshua J Van Veldhuizen

Yasamin Moazami

Peter A Blomgren

Jeffrey E Kropf

Zhongdong Zhao

Joshua A Kaplan

Christopher T Clark

Jason K Perry

Taryn Campbell

Nicole Nava

Natalie Seeger

Devan Naduthambi

Lafe J Purvis, Ii

William John Watkins

Jennifer Alissa Loyer-Drew

Suet C Yeung

Julian A Codelli

James G Taylor

Hyung-Jung Pyun

Barton W Phillips

Eda Y Canales

Petr Jansa

Adam James Schrier

Michael Sangi

Roland D Saito

Marina Shatskikh

Laurent P Debien

Arthur Yeung

Nicholas Alexander Till

Lianhong Xu

Seung H Lee

Rick Andrew Lee

Zhimin Du

Marcin Stasiak

Daniel H Byun

William Baker

Shaopei Cai

Patrick J Salvo

Weng K Chang

Jesse M Jacobsen

Stephen D Holmbo

Heath A Weaver

Joshua I Kaplan

Josh Van Veldhuizen

Jonah J Chang

David L Kukla

Thomas J Paul

Kirk K Stevens

Joshua Van Veldhuizen

Lafe J Ii Purvis

Joshua Kaplan

Jennifer A Treiberg

Jerry Evarts

Gary Phillips

Lafe J Purvis

Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or deuterated analog thereof, a pharmaceutical composition comprising a compound of the present invention, together with a pharmaceutically acceptable excipient thereof, and a method of treating cancer with the same.

PARP7 inhibitors

The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Inhibitors of peptidylarginine deiminases

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

Quinoline derivatives

Compounds for inhibition of alpha 4 beta 7 integrin

Compounds for inhibition of &#x3b1;4&#x3b2;7 integrin

Imidazopyridine derivatives

The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein t, R, R, R, R, and Rare as described herein.

Phosphatidylinositol 3-kinase inhibitors

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein X, Y, Z, n, m', A&#x2032;, R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

The present application provides the compounds of formula I or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, n, R, R, R, R, R, and Rare as described herein.

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A', W, W, W, R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

The present application provides the compounds of formula I or IA 

The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (J), or pharmaceutically acceptable salts thereof, in which A, n, m, R, R, R, R, R, Rand Rare as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms. The present disclosure further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms.

The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein n, m, R, R, R, R, and Rare described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.

Growing community of inventors

Brier, WA, United States of America

Stephane Perreault